Bristol-Myers Squibb and Clovis Oncology to assess new cancer regimen

Bristol-Myers Squibb has announced a new collaboration with Clovis Oncology to assess the benefits of a new combination cancer regimen.

The clinical collaboration agreement will evaluate a combination of Bristol-Myers Squibb's immunotherapy Opdivo and Clovis Oncology's PARP inhibitor Rubraca in a series of clinical trials.

Phase III studies are being planned to evaluate the safety and efficacy of the regimen among patients with advanced ovarian cancer and advanced triple-negative breast cancers, while a phase II trial will assess the therapy's performance in metastatic castration-resistant prostate cancer.

The trials will be conducted in the US, Europe and other additional countries, with Clovis acting as study sponsor and conducting party for the ovarian cancer study, while Bristol-Myers Squibb takes on these responsibilities for the breast and prostate cancer studies.

Dr Fouad Namouni, head of oncology development at Bristol-Myers Squibb, said: "This clinical collaboration addresses areas of unmet medical need where the combination of Opdivo and Rubraca may lead to an additional treatment option for patients with difficult to treat cancers."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.